Number of the records: 1  

Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP

  1. 1.
    SYSNO ASEP0503586
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleAcquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP
    Author(s) Piggott, L. (GB)
    Silva, A. (GB)
    Robinson, T. (GB)
    Santiago-Gomez, A. (GB)
    Simoes, B. M. (GB)
    Becker, M. (DE)
    Fichtner, I. (DE)
    Anděra, Ladislav (BTO-N)
    Young, P. (GB)
    Morris, Ch. (GB)
    Barrett-Lee, P. (GB)
    Alchami, F. (GB)
    Piva, M. (ES)
    Vivanco, M. D. (ES)
    Clarke, R. B. (GB)
    Gee, J. (GB)
    Clarkson, R. (GB)
    Number of authors17
    Source TitleClinical Cancer Research. - : American Association for Cancer Research - ISSN 1078-0432
    Roč. 24, č. 10 (2018), s. 2452-2463
    Number of pages12 s.
    Languageeng - English
    CountryUS - United States
    KeywordsFLICE inhibitory protein recombinant tumor necrosis factor related apoptosis inducing ligand ; fulvestrant ; recombinant tumor necrosis factor related apoptosis inducing ligand
    Subject RIVFD - Oncology ; Hematology
    OECD categoryOncology
    Institutional supportBTO-N - RVO:86652036
    UT WOS000432329600024
    EID SCOPUS85046169877
    DOI10.1158/1078-0432.CCR-17-1381
    AnnotationPurpose: One third of ER-positive breast cancer patients who initially respond to endocrine therapy become resistant to treatment. Such treatment failure is associated with poor prognosis and remains an area of unmet clinical need. Here, we identify a specific posttranslational modification that occurs during endocrine resistance and which results in tumor susceptibility to the apoptosis-inducer TRAIL. This potentially offers a novel stratified approach to targeting endocrine-resistant breast cancer.
    WorkplaceInstitute of Biotechnology
    ContactMonika Kopřivová, Monika.Koprivova@ibt.cas.cz, Tel.: 325 873 700
    Year of Publishing2019
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.